Pharmaburst(R) 500: Optimized, Evolutionary ODT Performance
WILMINGTON, Del., Aug. 11 SPI Pharma, Inc., a leader in oral dispersible tablet (ODT) technologies with its patented Pharmaburst(R) and Pharmafreeze(TM) platforms, recently announced the launch of Pharmaburst(R) 500. Using proprietary technology with superior organoleptics, Pharmaburst(R) 500 will most certainly raise the bar in terms of performance and economics that formulators have come to expect from a quick-dissolve dosage form.
Studies show that Pharmaburst(R) 500 outperforms all of its direct competitors with respect to product functionality and organoleptics. It is easy to use, cost-effective and readily formulated with various actives to make robust orally disintegrating tablets (ODTs). The finished ODT can be manufactured internally rather than through outsourcing.
Pharmaburst(R) was the first off-the-shelf, patented, co-processed ODT excipient system introduced in the pharmaceutical market. It is still the only ODT excipient system included in the US FDA's Inactive Ingredient Guide (IIG). It is now being used in a wide variety of new and generic drug applications around the world by many leading multinationals and several top generic companies.
Oral dispersible drugs containing Pharmaburst(R) have been successfully launched in regulated and developing markets around the world for indications such as migraine, allergy, analgesics, anxiety, oncology, schizophrenia, depression, and Parkinson's.
For more information, please visit www.spipharma.com.
SOURCE SPI Pharma, Inc.
You May Also Like